Dysregulated pathways and differentially expressed proteins associated with adverse transfusion reactions in different types of platelet components.

Adverse transfusion reaction Bioinformatic analysis Common dysregulated proteins Mitochondrial disorder Platelet activation Platelet component Platelet proteome Untargeted label-free method

Journal

Journal of proteomics
ISSN: 1876-7737
Titre abrégé: J Proteomics
Pays: Netherlands
ID NLM: 101475056

Informations de publication

Date de publication:
30 04 2020
Historique:
received: 15 10 2019
revised: 28 01 2020
accepted: 19 02 2020
pubmed: 24 2 2020
medline: 22 6 2021
entrez: 24 2 2020
Statut: ppublish

Résumé

Platelet components (PCs) are occasionally associated with adverse transfusion reactions (ATRs). ATRs can occur regardless of the type of PC being transfused, whether it is a single-donor apheresis PC (SDA-PC) or a pooled PC (PPCs). The purpose of this study was to investigate the proteins and dysregulated pathways in both of the main types of PCs. The proteomic profiles of platelet pellets from SDA-PCs and PPCs involved in ATRs were analysed using the label-free LC-MS/MS method. Differentially expressed proteins with fold changes >|1.5| in clinical cases versus controls were characterised using bioinformatic tools (RStudio, GeneCodis3, and Ingenuity Pathways Analysis (IPA). The proteins were confirmed by western blotting. The common primary proteins found to be dysregulated in both types of PCs were the mitochondrial carnitine/acylcarnitine carrier protein (SLC25A20), multimerin-1 (MMRN1), and calumenin (CALU), which are associated with the important enrichment of platelet activation, platelet degranulation, and mitochondrial activity. Furthermore, this analysis revealed the involvement of commonly dysregulated canonical pathways, particularly mitochondrial dysfunction, platelet activation, and acute phase response. This proteomic analysis provided an interesting contribution to our understanding of the meticulous physiopathology of PCs associated with ATR. A larger investigation would assist in delineating the most relevant proteins to target within preventive transfusion safety strategies. BIOLOGICAL SIGNIFICANCE: Within platelet transfusion strategies, the two primary types of PCs predominantly processed in Europe, include (i) single donor apheresis PCs (SDA-PCs) from one donor and (ii) pooled PCs (PPCs). The current study used PCs from five buffy coats derived from five whole blood donations that were identical in ABO, RH1 and KEL1 groups. Both PC types were shown to be associated with the onset of an ATR in the transfused patient. Several common platelet proteins were found to be dysregulated in bags associated with ATR occurrences regardless of the type of PCs transfused and of their process. The dysregulated proteins included mitochondrial carnitine/acylcarnitine carrier protein (SLC25A20), which is involved in a fatty acid oxidation disorder; calumenin (CALU); and multimerin-1 (MMRN1), which is chiefly involved in platelet activation and degranulation. Dysregulated platelet protein pathways for ATRs that occurred with SDA-PCs and PPCs could support the dysregulated functions found in association with those three proteins. Those common platelet proteins may become candidates to define biomarkers associated with the onset of an ATR from PC transfusions, including monitoring during the quality steps of PC manufacturing, provided that the results are confirmed in larger cohorts. This study enriches our knowledge of platelet proteomics in PCs under pathological conditions.

Identifiants

pubmed: 32088354
pii: S1874-3919(20)30085-3
doi: 10.1016/j.jprot.2020.103717
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103717

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no conflicts of interest.

Auteurs

Chaker Aloui (C)

French Blood Bank (EFS) Auvergne-Rhône-Alpes, Saint-Etienne, France; GIMAP-EA3064, University of Lyon, Saint-Etienne, France.

Céline Barlier (C)

French Blood Bank (EFS) Auvergne-Rhône-Alpes, Saint-Etienne, France.

Danielle Awounou (D)

French Blood Bank (EFS) Auvergne-Rhône-Alpes, Saint-Etienne, France.

Saliou Thiam (S)

French Blood Bank (EFS) Auvergne-Rhône-Alpes, Saint-Etienne, France.

Jocelyne Fagan (J)

French Blood Bank (EFS) Auvergne-Rhône-Alpes, Saint-Etienne, France; GIMAP-EA3064, University of Lyon, Saint-Etienne, France.

Stéphane Claverol (S)

Proteome Platform, CGFB, University of Bordeaux Segalen, Bordeaux, France.

Emmanuelle Tavernier (E)

Cancerology Institute Lucien Neuwirth, Saint-Priest-en-Jarez, France.

Christiane Mounier (C)

Cancerology Institute Lucien Neuwirth, Saint-Priest-en-Jarez, France.

Hind Hamzeh-Cognasse (H)

GIMAP-EA3064, University of Lyon, Saint-Etienne, France.

Fabrice Cognasse (F)

French Blood Bank (EFS) Auvergne-Rhône-Alpes, Saint-Etienne, France; GIMAP-EA3064, University of Lyon, Saint-Etienne, France.

Olivier Garraud (O)

GIMAP-EA3064, University of Lyon, Saint-Etienne, France; National Institute of Blood Transfusion (INTS), Paris, France.

Sandrine Laradi (S)

French Blood Bank (EFS) Auvergne-Rhône-Alpes, Saint-Etienne, France; GIMAP-EA3064, University of Lyon, Saint-Etienne, France. Electronic address: sandrine.laradi@efs.sante.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH